Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Befa11f76a54df8b903474f17620b11d4> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Befa11f76a54df8b903474f17620b11d4 NCIT_P378 "NCI" @default.
- Befa11f76a54df8b903474f17620b11d4 type Axiom @default.
- Befa11f76a54df8b903474f17620b11d4 annotatedProperty IAO_0000115 @default.
- Befa11f76a54df8b903474f17620b11d4 annotatedSource NCIT_C179622 @default.
- Befa11f76a54df8b903474f17620b11d4 annotatedTarget "A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) encoding human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) coupled to the co-immunostimulatory signaling domain 4-1BB, normally expressed on T-cells, and linked to the intracellular CD3 zeta domain (CD3z), which is needed for TCR signaling, with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR T cells KD-025 specifically recognize and bind to tumor cells expressing NKG2D ligands (NKG2DLs), resulting in cytokine secretion and lysis of NKG2D ligand-expressing tumor cells. NKG2DLs, such as MICA, MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on a variety of cancer cell types, but are not expressed on most normal, healthy cells." @default.